Jambuwala Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 6.10 Cr
as on 03-12-2024
- Paid Up Capital ₹ 6.09 Cr
as on 03-12-2024
- Company Age 7 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 10.60 Cr
as on 03-12-2024
- Revenue 4625.82%
(FY 2021)
- Profit -6972.65%
(FY 2021)
- Ebitda 6242.97%
(FY 2021)
- Net Worth -17.53%
(FY 2021)
- Total Assets 4.95%
(FY 2021)
About Jambuwala Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 6.10 Cr and a paid-up capital of Rs 6.09 Cr.
The company currently has active open charges totaling ₹10.60 Cr.
Kamal Shah, Pranlal Shah, and Rasilaben Shah serve as directors at the Company.
- CIN/LLPIN
U24100GJ2017PLC098725
- Company No.
098725
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
17 Aug 2017
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Jambuwala Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kamal Shah  | Director | 17-Aug-2017 | Current |
| Pranlal Shah | Director | 17-Aug-2017 | Current |
| Rasilaben Shah | Director | 17-Aug-2024 | Current |
Financial Performance of Jambuwala Pharmaceuticals.
Jambuwala Pharmaceuticals Limited, for the financial year ended 2021, experienced significant growth in revenue, with a 4625.82% increase. The company also saw a substantial fall in profitability, with a 6972.65% decrease in profit. The company's net worth observed a substantial decline by a decrease of 17.53%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Jambuwala Pharmaceuticals?
In 2021, Jambuwala Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Jambuwala International Ifsc Private LimitedActive 7 years 11 monthsKamal Shah and Pranlal Shah are mutual person
Jambuwala Commodities Private LimitedActive 16 years 9 monthsKamal Shah, Pranlal Shah and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Sidbi Creation Date: 01 Mar 2019 | ₹10.60 Cr | Open |
How Many Employees Work at Jambuwala Pharmaceuticals?
Jambuwala Pharmaceuticals has a workforce of 34 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Jambuwala Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Jambuwala Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
